# Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD

> **NCT04882124** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 38 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** CSJ117
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04882124
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-24
- **Primary completion:** 2022-09-15
- **Final completion:** 2022-09-15
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2022-11-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04882124

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04882124, "Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04882124. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*